{Reference Type}: Journal Article
{Title}: Personalized medicine in acromegaly: The ACROFAST study.
{Author}: Marques-Pamies M;Gil J;Sampedro-Nuñez M;Valassi E;Biagetti B;Giménez-Palop O;Hernández M;Martínez S;Carrato C;Villar-Taibo R;Araujo-Castro M;Blanco C;Simón-Muela I;Simó-Servat A;Xifra G;Vázquez F;Pavón I;Rosado JA;García-Centeno R;Zavala R;Hanzu FA;Mora M;Aulinas A;Vilarrasa N;Librizzi S;Calatayud M;de Miguel P;Alvarez-Escola C;Picó A;Salinas I;Fajardo-Montañana C;Cámara R;Bernabéu I;Jordà M;Webb SM;Marazuela M;Puig-Domingo M;
{Journal}: J Clin Endocrinol Metab
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jun 29
{Factor}: 6.134
{DOI}: 10.1210/clinem/dgae444
{Abstract}: Medical treatment of acromegaly is currently performed through a trial-error approach using first generation somatostatin receptor ligands (fgSRLs) as first-line drugs, with an effectiveness of about 50%, and subsequent drugs are indicated through clinical judgment. Some biomarkers can predict fgSRLs response. Here we report the results of the ACROFAST study, a clinical trial in which a protocol based on predictive biomarkers of fgSRLs was evaluated.<BR><B>METHODS: </B>prospective trial (21 university hospitals) comparing the effectiveness and time-to control of two treatment protocols during 12 months: A) A personalized protocol in which first option were fgSRLs as monotherapy or in combination with pegvisomant or, pegvisomant as monotherapy depending on the short Acute Octreotide Test (sAOT) results, tumor T2 Magnetic Resonance (MRI) signal or immunostaining for E-cadherin and, B) A control group with treatment always started by fgSRLs and the other drugs included after demonstrating inadequate control.<BR><B>RESULTS: </B>Eighty-five patients participated; 45 in the personalized and 40 in the control group. More patients in the personalized protocol achieved hormonal control compared to those in the control group (78% vs 53%, p < 0.05). Survival analysis revealed a hazard ratio for achieving hormonal control adjusted by age and sex of 2.53 (CI 1.30-4.80). Patients from personalized arm were controlled in a shorter period of time (p = 0.01).<BR><B>CONCLUSIONS: </B>Personalized medicine is feasible using a relatively simple protocol and allows a higher number of patients achieving control in a shorter period of time.